ARTICLE | Clinical News

EDP-788: Development discontinued

January 19, 2015 8:00 AM UTC

Enanta disclosed in an SEC filing that it is discontinuing its antibiotic program to treat Gram-positive bacterial infections for non-biodefense indications, including EDP-788, primarily based on the “competitive landscape.” Under a 2011 contract, NIH’s National Institute of Allergy and Infectious Disease (NIAID) was funding preclinical and early clinical development of EDP-788 for use as a medical biodefense countermeasure. However, Enanta does not expect NIAID to pursue development of EDP-788 solely for biodefense purposes and expects the agency to end the contract. EDP-788 was in Phase I testing (see BioCentury, Oct. 17, 2011 & Sept. 9, 2013). ...